VCAM1 and Schnyder corneal dystrophy: A recent phase II clinical trial of pentosan polysulfate sodium (PPS), an orally available heparin compound, improved microvascular flow and reduced serum VCAM-1 levels in SCD patients, but did not reduce daily pain scores [23], prompting us to search for novel P-selectin inhibitors.